Trial Profile
Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Carcinoma; Endometrial cancer; Leiomyosarcoma; Sarcoma; Uterine cancer
- Focus Therapeutic Use
- 03 Apr 2024 Status changed from active, no longer recruiting to completed.
- 04 Apr 2023 Planned End Date changed from 1 Aug 2023 to 1 Aug 2024.
- 04 Apr 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2024.